{
    "info": {
        "nct_id": "NCT03512405",
        "official_title": "A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia",
        "inclusion_criteria": "* Previously treated ALL including philadelphia chromosome (BCR-Ab1) positive ALL who meet all of the following criteria:\n\n  * Diagnosis of CD19-positive B-cell ALL based on the flow cytometry and histology\n  * Previously treated subjects with primary refractory disease OR after first or subsequent relapse\n  * Subjects with detectable lymphoblasts in bone marrow (BM) or extramedullary disease (EMD) that is radiographically measurable and amenable to repeat biopsies\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Left ventricular ejection fraction (LVEF) > 45%\n* Pulmonary function tests diffusing capacity of the lungs for carbon monoxide (DLCO) (adjusted for hemoglobin) > 50% predicted\n* Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 ml/min for subject with creatinine levels > 1.5 X institutional ULN\n* Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases\n* Albumin >= 2.5 mg/dL\n* International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants\n* Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n* Beta human chorionic gonadotropin (beta HCG) negative\n* Human immunodeficiency virus (HIV): negative HIV antibody / polymerase chain reaction (PCR)\n* Hepatitis B virus (HBV): negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc) antibody or positive HBc and negative HBV deoxyribonucleic acid (DNA) by quantitative PCR\n* Hepatitis C virus (HCV): negative viral ribonucleic acid (RNA) (if HCV antibody is positive)\n* Required screening laboratory data (within 28 days prior to administration of pembrolizumab)\n* Discontinuation of all therapy (including radiotherapy, chemotherapy, tyrosine-kinase inhibitors [TKIs], immunotherapy or investigational therapy) for the treatment of cancer as follows:\n\n  * At least 1 week or 5 half-lives (whichever is longer) from the last dose of prior anti-cancer therapy and the initiation of study therapy\n  * Exceptions or modifications to the above are as follows:\n\n    * Medications that are typically part of a maintenance therapy for ALL, such as glucocorticoids or mercaptopurine, may be administered up to 3 days prior to the first dose, except vinca alkaloids which must be discontinued at least 14 days prior to the start of study treatment; TKIs are not permitted to be continued at screening (e.g. Gleevec)\n  * Intrathecal (IT) chemotherapy may be dosed up to 7 days prior to first dose of pembrolizumab (cytarabine [Ara-C] recommended)\n  * For biologics (e.g. monoclonal antibodies), washout period of 1 month beyond the recommended dosing interval and at least 4 weeks or 5 half-lives (whichever is longer) since the last dose\n* All acute toxic effects of any prior antitumor therapy must be resolved to grade =< 1 before enrollment, with the exception of alopecia (any grade permitted), or bone marrow parameters (any grades permitted)\n* For female subjects of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 concurrent protocol recommended methods of contraception from the screening visit throughout the study treatment period and to 30 days from the last dose of pembrolizumab; a negative serum pregnancy test is required for female subjects at screening; lactating females must agree to discontinue nursing before administration of study drugs\n* For male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 protocol-recommended methods of contraception from the start of pembrolizumab throughout the study treatment period and for 90 days following the last dose of pembrolizumab; also, male subjects should refrain from sperm donation from the start of pembrolizumab throughout the study treatment period and for 3 months following the last dose of study drugs\n* In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's ALL\n* Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions; psychological, social, familial or geographical factors that might preclude adequate study participation should be considered\n* Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Diagnosis of mature B-cell ALL (Burkitt's leukemia) according to World Health Organization (WHO) classification, or lymphoid blast crisis of chronic myelogenous leukemia (CML)\n* A life threatening illness, medical condition or organ system dysfunction which, in the investigators' opinion, could compromise the subject's safety or interfere with the absorption or metabolism of pembrolizumab\n* Active or symptomatic central nervous system (CNS) disease\n\n  * For study purposes, a subject will not be considered as having active CNS disease if the subject has documentation of prior CNS disease and has received prior treatment (IT or radiation) and is:\n\n    * Asymptomatic for the last 28 days prior to screening and\n    * Has documented at least 2 negative cerebrospinal fluid (CSF) cytology (which must include 1 lumbar puncture [LP] within the study screening window)\n* Uncontrolled undercurrent illness including but not limited to unstable angina pectoris or psychiatric illness/social situations that would limit compliance with study requirements; subjects with active infection are permitted to enroll provided that the infection is documented to be under control\n* History of myelodysplastic syndrome or organ transplantation\n* History of non-lymphoid malignancy except for the following:\n\n  * Adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requirement only hormonal therapy and with normal prostate specific antigen for > 1 year prior to the start of pembrolizumab, or any other cancer that has been in complete remission without treatment for >= 5 years prior to enrollment\n* Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab\n* Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), HIV, alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, or portal hypertension\n* Prior allogeneic bone marrow transplantation\n* Pregnancy or breastfeeding\n* Has known history of, or any evidence of active, non-infectious pneumonitis\n* Concurrent participation in an investigational drug trial with therapeutic intent defined as prior study therapy within 28 days prior to start of this study\n* Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\n\n  * Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\n  * Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or blinatumomab\n* Has received a live vaccine within 30 days of planned start of study therapy\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Diagnosis of CD19-positive B-cell ALL based on the flow cytometry and histology",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of CD19-positive B-cell ALL",
                    "criterion": "B-cell acute lymphoblastic leukemia (ALL)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CD19-positive",
                    "criterion": "CD19 expression on B-cell ALL",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "based on the flow cytometry and histology",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "flow cytometry",
                                "histology"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously treated subjects with primary refractory disease OR after first or subsequent relapse",
            "criterions": [
                {
                    "exact_snippets": "Previously treated subjects with primary refractory disease",
                    "criterion": "primary refractory disease",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": "primary refractory"
                        }
                    ]
                },
                {
                    "exact_snippets": "Previously treated subjects ... after first or subsequent relapse",
                    "criterion": "disease relapse",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": "relapsed (first or subsequent)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with detectable lymphoblasts in bone marrow (BM) or extramedullary disease (EMD) that is radiographically measurable and amenable to repeat biopsies",
            "criterions": [
                {
                    "exact_snippets": "detectable lymphoblasts in bone marrow (BM)",
                    "criterion": "lymphoblasts in bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "extramedullary disease (EMD) that is radiographically measurable and amenable to repeat biopsies",
                    "criterion": "extramedullary disease",
                    "requirements": [
                        {
                            "requirement_type": "radiographically measurable",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "amenable to repeat biopsies",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) > 45%",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) > 45%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pulmonary function tests diffusing capacity of the lungs for carbon monoxide (DLCO) (adjusted for hemoglobin) > 50% predicted",
            "criterions": [
                {
                    "exact_snippets": "Pulmonary function tests diffusing capacity of the lungs for carbon monoxide (DLCO) (adjusted for hemoglobin) > 50% predicted",
                    "criterion": "diffusing capacity of the lungs for carbon monoxide (DLCO)",
                    "requirements": [
                        {
                            "requirement_type": "adjustment",
                            "expected_value": "adjusted for hemoglobin"
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "% predicted"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 ml/min for subject with creatinine levels > 1.5 X institutional ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 X upper limit of normal (ULN)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "measured or calculated creatinine clearance ... >= 60 ml/min for subject with creatinine levels > 1.5 X institutional ULN",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "applicability_condition",
                            "expected_value": "for subject with creatinine levels > 1.5 X institutional ULN"
                        }
                    ]
                },
                {
                    "exact_snippets": "glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]",
                    "criterion": "glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "alternative_measure",
                            "expected_value": "can be used in place of creatinine or creatinine clearance"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum total bilirubin =< 1.5 X ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for subjects with total bilirubin levels > 1.5 ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously treated ALL including philadelphia chromosome (BCR-Ab1) positive ALL who meet all of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Previously treated ALL",
                    "criterion": "acute lymphoblastic leukemia (ALL)",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "philadelphia chromosome (BCR-Ab1) positive ALL",
                    "criterion": "philadelphia chromosome (BCR-Ab1) positivity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN",
                    "criterion": "INR or PT",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants",
                    "criterion": "PT or PTT (in subjects receiving anticoagulant therapy)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Beta human chorionic gonadotropin (beta HCG) negative",
            "criterions": [
                {
                    "exact_snippets": "Beta human chorionic gonadotropin (beta HCG) negative",
                    "criterion": "beta human chorionic gonadotropin (beta HCG)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "Activated partial thromboplastin time (aPTT) =< 1.5 X ULN",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants",
                    "criterion": "prothrombin time (PT) or partial thromboplastin time (PTT) while on anticoagulant therapy",
                    "requirements": [
                        {
                            "requirement_type": "therapeutic range",
                            "expected_value": "within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Human immunodeficiency virus (HIV): negative HIV antibody / polymerase chain reaction (PCR)",
            "criterions": [
                {
                    "exact_snippets": "Human immunodeficiency virus (HIV): negative HIV antibody / polymerase chain reaction (PCR)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic test result",
                            "expected_value": [
                                "negative HIV antibody",
                                "negative HIV PCR"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatitis C virus (HCV): negative viral ribonucleic acid (RNA) (if HCV antibody is positive)",
            "criterions": [
                {
                    "exact_snippets": "Hepatitis C virus (HCV): negative viral ribonucleic acid (RNA) (if HCV antibody is positive)",
                    "criterion": "Hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "HCV RNA status",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "HCV antibody status",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Required screening laboratory data (within 28 days prior to administration of pembrolizumab)",
            "criterions": [
                {
                    "exact_snippets": "Required screening laboratory data (within 28 days prior to administration of pembrolizumab)",
                    "criterion": "screening laboratory data",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to administration of pembrolizumab"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatitis B virus (HBV): negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc) antibody or positive HBc and negative HBV deoxyribonucleic acid (DNA) by quantitative PCR",
            "criterions": [
                {
                    "exact_snippets": "negative hepatitis B surface antigen (HBsAg)",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "negative hepatitis B core (HBc) antibody or positive HBc and negative HBV deoxyribonucleic acid (DNA) by quantitative PCR",
                    "criterion": "hepatitis B core (HBc) antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "alternative",
                            "expected_value": "positive HBc and negative HBV DNA"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive HBc and negative HBV deoxyribonucleic acid (DNA) by quantitative PCR",
                    "criterion": "hepatitis B core (HBc) antibody and HBV deoxyribonucleic acid (DNA)",
                    "requirements": [
                        {
                            "requirement_type": "HBc antibody presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HBV DNA presence (by quantitative PCR)",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Discontinuation of all therapy (including radiotherapy, chemotherapy, tyrosine-kinase inhibitors [TKIs], immunotherapy or investigational therapy) for the treatment of cancer as follows:",
            "criterions": [
                {
                    "exact_snippets": "Discontinuation of all therapy (including radiotherapy, chemotherapy, tyrosine-kinase inhibitors [TKIs], immunotherapy or investigational therapy) for the treatment of cancer",
                    "criterion": "cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy_types",
                            "expected_value": [
                                "radiotherapy",
                                "chemotherapy",
                                "tyrosine-kinase inhibitors (TKIs)",
                                "immunotherapy",
                                "investigational therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 1 week or 5 half-lives (whichever is longer) from the last dose of prior anti-cancer therapy and the initiation of study therapy",
            "criterions": [
                {
                    "exact_snippets": "At least 1 week or 5 half-lives (whichever is longer) from the last dose of prior anti-cancer therapy and the initiation of study therapy",
                    "criterion": "interval between last dose of prior anti-cancer therapy and initiation of study therapy",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "week"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intrathecal (IT) chemotherapy may be dosed up to 7 days prior to first dose of pembrolizumab (cytarabine [Ara-C] recommended)",
            "criterions": [
                {
                    "exact_snippets": "Intrathecal (IT) chemotherapy may be dosed up to 7 days prior to first dose of pembrolizumab",
                    "criterion": "intrathecal chemotherapy administration",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to pembrolizumab",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cytarabine [Ara-C] recommended",
                    "criterion": "intrathecal chemotherapy agent",
                    "requirements": [
                        {
                            "requirement_type": "agent recommended",
                            "expected_value": "cytarabine (Ara-C)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Medications that are typically part of a maintenance therapy for ALL, such as glucocorticoids or mercaptopurine, may be administered up to 3 days prior to the first dose, except vinca alkaloids which must be discontinued at least 14 days prior to the start of study treatment; TKIs are not permitted to be continued at screening (e.g. Gleevec)",
            "criterions": [
                {
                    "exact_snippets": "glucocorticoids or mercaptopurine, may be administered up to 3 days prior to the first dose",
                    "criterion": "administration of glucocorticoids or mercaptopurine",
                    "requirements": [
                        {
                            "requirement_type": "administration window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "days prior to first dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "vinca alkaloids which must be discontinued at least 14 days prior to the start of study treatment",
                    "criterion": "discontinuation of vinca alkaloids",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation window",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days prior to start of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "TKIs are not permitted to be continued at screening (e.g. Gleevec)",
                    "criterion": "continuation of TKIs at screening",
                    "requirements": [
                        {
                            "requirement_type": "continuation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For biologics (e.g. monoclonal antibodies), washout period of 1 month beyond the recommended dosing interval and at least 4 weeks or 5 half-lives (whichever is longer) since the last dose",
            "criterions": [
                {
                    "exact_snippets": "For biologics (e.g. monoclonal antibodies), washout period of 1 month beyond the recommended dosing interval",
                    "criterion": "biologics (e.g. monoclonal antibodies) washout period",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month beyond the recommended dosing interval"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 4 weeks or 5 half-lives (whichever is longer) since the last dose",
                    "criterion": "time since last dose of biologics (e.g. monoclonal antibodies)",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "at least 4 weeks",
                                "5 half-lives (whichever is longer)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All acute toxic effects of any prior antitumor therapy must be resolved to grade =< 1 before enrollment, with the exception of alopecia (any grade permitted), or bone marrow parameters (any grades permitted)",
            "criterions": [
                {
                    "exact_snippets": "All acute toxic effects of any prior antitumor therapy must be resolved to grade =< 1 before enrollment",
                    "criterion": "acute toxic effects of prior antitumor therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of alopecia (any grade permitted)",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "any grade permitted"
                        }
                    ]
                },
                {
                    "exact_snippets": "bone marrow parameters (any grades permitted)",
                    "criterion": "bone marrow parameters",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "any grade permitted"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures",
            "criterions": [
                {
                    "exact_snippets": "Have the ability to understand and sign a written informed consent form",
                    "criterion": "ability to understand and sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "informed consent form, which must be obtained prior to initiation of study procedures",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "obtained prior to study procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 protocol-recommended methods of contraception from the start of pembrolizumab throughout the study treatment period and for 90 days following the last dose of pembrolizumab; also, male subjects should refrain from sperm donation from the start of pembrolizumab throughout the study treatment period and for 3 months following the last dose of study drugs",
            "criterions": [
                {
                    "exact_snippets": "male subjects having intercourse with females of childbearing potential",
                    "criterion": "male subjects having intercourse with females of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to abstain from heterosexual intercourse or use 2 protocol-recommended methods of contraception from the start of pembrolizumab throughout the study treatment period and for 90 days following the last dose of pembrolizumab",
                    "criterion": "contraception during and after pembrolizumab treatment",
                    "requirements": [
                        {
                            "requirement_type": "contraception_method",
                            "expected_value": [
                                "abstinence",
                                "2 protocol-recommended methods"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "start of pembrolizumab"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 90,
                                        "unit": "days after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "male subjects should refrain from sperm donation from the start of pembrolizumab throughout the study treatment period and for 3 months following the last dose of study drugs",
                    "criterion": "sperm donation during and after pembrolizumab treatment",
                    "requirements": [
                        {
                            "requirement_type": "sperm_donation",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "start of pembrolizumab"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Albumin >= 2.5 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Albumin >= 2.5 mg/dL",
                    "criterion": "albumin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions; psychological, social, familial or geographical factors that might preclude adequate study participation should be considered",
            "criterions": [
                {
                    "exact_snippets": "Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions",
                    "criterion": "willingness to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychological, social, familial or geographical factors that might preclude adequate study participation should be considered",
                    "criterion": "psychological, social, familial or geographical factors affecting study participation",
                    "requirements": [
                        {
                            "requirement_type": "absence of factors precluding participation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For female subjects of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 concurrent protocol recommended methods of contraception from the screening visit throughout the study treatment period and to 30 days from the last dose of pembrolizumab; a negative serum pregnancy test is required for female subjects at screening; lactating females must agree to discontinue nursing before administration of study drugs",
            "criterions": [
                {
                    "exact_snippets": "female subjects of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 concurrent protocol recommended methods of contraception from the screening visit throughout the study treatment period and to 30 days from the last dose of pembrolizumab",
                    "criterion": "female subjects of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "willingness to abstain from heterosexual intercourse or use 2 concurrent protocol recommended methods of contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception/abstinence",
                            "expected_value": "from the screening visit throughout the study treatment period and to 30 days from the last dose of pembrolizumab"
                        }
                    ]
                },
                {
                    "exact_snippets": "a negative serum pregnancy test is required for female subjects at screening",
                    "criterion": "serum pregnancy test at screening",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating females must agree to discontinue nursing before administration of study drugs",
                    "criterion": "lactating females",
                    "requirements": [
                        {
                            "requirement_type": "agreement to discontinue nursing before administration of study drugs",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's ALL",
            "criterions": [
                {
                    "exact_snippets": "In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's ALL",
                    "criterion": "benefit-to-risk ratio of protocol participation",
                    "requirements": [
                        {
                            "requirement_type": "acceptability (as judged by investigator)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",
            "criterions": [
                {
                    "exact_snippets": "Has known psychiatric or substance abuse disorders",
                    "criterion": "psychiatric disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known psychiatric or substance abuse disorders",
                    "criterion": "substance abuse disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "would interfere with cooperation with the requirements of the trial",
                    "criterion": "ability to cooperate with trial requirements",
                    "requirements": [
                        {
                            "requirement_type": "interference by disorder",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received a live vaccine within 30 days of planned start of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Has received a live vaccine within 30 days of planned start of study therapy",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of non-lymphoid malignancy except for the following:",
            "criterions": [
                {
                    "exact_snippets": "History of non-lymphoid malignancy",
                    "criterion": "history of non-lymphoid malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of mature B-cell ALL (Burkitt's leukemia) according to World Health Organization (WHO) classification, or lymphoid blast crisis of chronic myelogenous leukemia (CML)",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of mature B-cell ALL (Burkitt's leukemia) according to World Health Organization (WHO) classification",
                    "criterion": "mature B-cell ALL (Burkitt's leukemia) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "classification_system",
                            "expected_value": "World Health Organization (WHO)"
                        }
                    ]
                },
                {
                    "exact_snippets": "lymphoid blast crisis of chronic myelogenous leukemia (CML)",
                    "criterion": "lymphoid blast crisis of chronic myelogenous leukemia (CML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known history of, or any evidence of active, non-infectious pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "Has known history of, or any evidence of active, non-infectious pneumonitis",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab",
                    "criterion": "hypersensitivity to pembrolizumab or blinatumomab (active substance or excipients)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab",
                    "criterion": "intolerance to pembrolizumab or blinatumomab (active substance or excipients)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Asymptomatic for the last 28 days prior to screening and",
            "criterions": [
                {
                    "exact_snippets": "Asymptomatic for the last 28 days prior to screening",
                    "criterion": "symptoms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment",
            "criterions": [
                {
                    "exact_snippets": "Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs)",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment",
                    "criterion": "replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "considered systemic treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent participation in an investigational drug trial with therapeutic intent defined as prior study therapy within 28 days prior to start of this study",
            "criterions": [
                {
                    "exact_snippets": "Concurrent participation in an investigational drug trial with therapeutic intent",
                    "criterion": "participation in an investigational drug trial with therapeutic intent",
                    "requirements": [
                        {
                            "requirement_type": "concurrent participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior study therapy within 28 days prior to start of this study",
                    "criterion": "prior study therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since prior study therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requirement only hormonal therapy and with normal prostate specific antigen for > 1 year prior to the start of pembrolizumab, or any other cancer that has been in complete remission without treatment for >= 5 years prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated local basal cell or squamous cell carcinoma of the skin",
                    "criterion": "basal cell or squamous cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        },
                        {
                            "requirement_type": "localization",
                            "expected_value": "local"
                        }
                    ]
                },
                {
                    "exact_snippets": "cervical carcinoma in situ",
                    "criterion": "cervical carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "superficial bladder cancer",
                    "criterion": "superficial bladder cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requirement only hormonal therapy and with normal prostate specific antigen for > 1 year prior to the start of pembrolizumab",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "symptoms",
                            "expected_value": "asymptomatic"
                        },
                        {
                            "requirement_type": "metastatic disease",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "therapy requirement",
                            "expected_value": [
                                "no requirement for therapy",
                                "requirement only hormonal therapy"
                            ]
                        },
                        {
                            "requirement_type": "prostate specific antigen",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "normal"
                            }
                        },
                        {
                            "requirement_type": "duration of normal PSA",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other cancer that has been in complete remission without treatment for >= 5 years prior to enrollment",
                    "criterion": "other cancer in complete remission",
                    "requirements": [
                        {
                            "requirement_type": "remission status",
                            "expected_value": "complete remission"
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "without treatment"
                        },
                        {
                            "requirement_type": "duration of remission",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent",
            "criterions": [
                {
                    "exact_snippets": "Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1",
                    "criterion": "prior chemotherapy, targeted small molecule therapy, or radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent",
                    "criterion": "recovery from adverse events due to a previously administered agent",
                    "requirements": [
                        {
                            "requirement_type": "adverse event severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "recovery to baseline",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active or symptomatic central nervous system (CNS) disease",
            "criterions": [
                {
                    "exact_snippets": "Active or symptomatic central nervous system (CNS) disease",
                    "criterion": "central nervous system (CNS) disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled undercurrent illness including but not limited to unstable angina pectoris or psychiatric illness/social situations that would limit compliance with study requirements; subjects with active infection are permitted to enroll provided that the infection is documented to be under control",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled undercurrent illness including but not limited to unstable angina pectoris",
                    "criterion": "undercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "stable"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "does not limit compliance"
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with active infection are permitted to enroll provided that the infection is documented to be under control",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "under control"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic bone marrow transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic bone marrow transplantation",
                    "criterion": "allogeneic bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy",
            "criterions": [
                {
                    "exact_snippets": "if subject received major surgery",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "history of major surgery",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy",
                    "criterion": "recovery from toxicity and/or complications of major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": "adequate"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to starting therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment",
            "criterions": [
                {
                    "exact_snippets": "Is currently participating and receiving study therapy",
                    "criterion": "participation in a study and receiving study therapy",
                    "requirements": [
                        {
                            "requirement_type": "current participation and therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment",
                    "criterion": "prior participation in a study and receipt of investigational therapy or device",
                    "requirements": [
                        {
                            "requirement_type": "participation in study",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "receipt of investigational therapy or device",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since last investigational therapy or device",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has documented at least 2 negative cerebrospinal fluid (CSF) cytology (which must include 1 lumbar puncture [LP] within the study screening window)",
            "criterions": [
                {
                    "exact_snippets": "Has documented at least 2 negative cerebrospinal fluid (CSF) cytology",
                    "criterion": "cerebrospinal fluid (CSF) cytology",
                    "requirements": [
                        {
                            "requirement_type": "number of negative results",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "results"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "which must include 1 lumbar puncture [LP] within the study screening window",
                    "criterion": "lumbar puncture (LP) for CSF cytology within the study screening window",
                    "requirements": [
                        {
                            "requirement_type": "number of lumbar punctures within screening window",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lumbar puncture"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A life threatening illness, medical condition or organ system dysfunction which, in the investigators' opinion, could compromise the subject's safety or interfere with the absorption or metabolism of pembrolizumab",
            "criterions": [
                {
                    "exact_snippets": "A life threatening illness, medical condition or organ system dysfunction",
                    "criterion": "life threatening illness, medical condition or organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "which, in the investigators' opinion, could compromise the subject's safety",
                    "criterion": "compromise the subject's safety",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "which, in the investigators' opinion, could ... interfere with the absorption or metabolism of pembrolizumab",
                    "criterion": "interference with absorption or metabolism of pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "interference",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment",
            "criterions": [
                {
                    "exact_snippets": "Is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive ... within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment",
                    "criterion": "expectation to conceive",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "from pre-screening or screening visit through 120 days after the last dose of trial treatment"
                        },
                        {
                            "requirement_type": "expectation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to ... father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment",
                    "criterion": "expectation to father children",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "from pre-screening or screening visit through 120 days after the last dose of trial treatment"
                        },
                        {
                            "requirement_type": "expectation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study",
            "criterions": [
                {
                    "exact_snippets": "=< grade 2 neuropathy",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For study purposes, a subject will not be considered as having active CNS disease if the subject has documentation of prior CNS disease and has received prior treatment (IT or radiation) and is:",
            "criterions": [
                {
                    "exact_snippets": "subject will not be considered as having active CNS disease if the subject has documentation of prior CNS disease and has received prior treatment (IT or radiation)",
                    "criterion": "CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "history/documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": [
                                "IT",
                                "radiation"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or blinatumomab",
            "criterions": [
                {
                    "exact_snippets": "Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or blinatumomab",
                    "criterion": "prior therapy with anti-PD-1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or blinatumomab",
                    "criterion": "prior therapy with anti-PD-L1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or blinatumomab",
                    "criterion": "prior therapy with anti-PD-L2 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or blinatumomab",
                    "criterion": "prior therapy with blinatumomab",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), HIV, alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, or portal hypertension",
            "criterions": [
                {
                    "exact_snippets": "Ongoing drug-induced liver injury",
                    "criterion": "drug-induced liver injury",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic active hepatitis C (HCV)",
                    "criterion": "chronic active hepatitis C (HCV)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic active hepatitis B (HBV)",
                    "criterion": "chronic active hepatitis B (HBV)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alcoholic liver disease",
                    "criterion": "alcoholic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non-alcoholic steatohepatitis",
                    "criterion": "non-alcoholic steatohepatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis of the liver",
                    "criterion": "cirrhosis of the liver",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "portal hypertension",
                    "criterion": "portal hypertension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for subjects with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine transaminase (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases",
                    "criterion": "alanine transaminase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for subjects with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exceptions or modifications to the above are as follows:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "* History of myelodysplastic syndrome or organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "History of myelodysplastic syndrome",
                    "criterion": "myelodysplastic syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... organ transplantation",
                    "criterion": "organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}